{"groups":[{"description":"Busulfan starting dose of 32 mg/m\\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m\\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.","id":"FG000","title":"Busulfan + Fludarabine + Cyclophosphamide"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"56"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"49"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Recruitment Period: September 02, 2008 to December 12, 2011. All recruitment was done at The University of Texas (UT) MD Anderson Cancer Center."}